Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients
NCT ID: NCT03032848
Last Updated: 2019-05-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
69 participants
INTERVENTIONAL
2013-11-26
2016-12-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse
NCT00803335
Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery
NCT07030426
Study to Evaluate the Equivalence of Estradiol Vaginal Cream to Reference Standard in the Treatment of Vaginal Atrophy
NCT03332303
Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function
NCT03493126
Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream
NCT04232813
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Conjugated Estrogen Group
use of 1 gram per day
Promestriene
use of 1 gram per day
Estriol
use of 1 gram per day
Vaginal Moisturizer - Cream
use of 1 gram per day
Promestriene Group
use of 1 gram per day
Conjugated Estrogen
use of 1 gram per day
Estriol
use of 1 gram per day
Vaginal Moisturizer - Cream
use of 1 gram per day
Estriol Group
use of 1 gram per day
Conjugated Estrogen
use of 1 gram per day
Promestriene
use of 1 gram per day
Vaginal Moisturizer - Cream
use of 1 gram per day
Vaginal Moisturizer Cream
use of 1 gram per day
Conjugated Estrogen
use of 1 gram per day
Promestriene
use of 1 gram per day
Estriol
use of 1 gram per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Conjugated Estrogen
use of 1 gram per day
Promestriene
use of 1 gram per day
Estriol
use of 1 gram per day
Vaginal Moisturizer - Cream
use of 1 gram per day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* normal oncotic cytology and mammogram
* any grade of pelvic organ prolapse with surgery indication and ultrasound with endometrium measure less than 5 mm
Exclusion Criteria
* hormonal replacement on the past three months
* renal or hepatic desease
* porfiria
* past venous thromboembolism; ulcerated prolapse
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidade Federal do Paraná
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Elisa Chicareli Pinhat
Doctor
References
Explore related publications, articles, or registry entries linked to this study.
Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013 Sep;20(9):888-902; quiz 903-4. doi: 10.1097/GME.0b013e3182a122c2.
Taithongchai A, Johnson EE, Ismail SI, Barron-Millar E, Kernohan A, Thakar R. Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women. Cochrane Database Syst Rev. 2023 Jul 11;7(7):CD014592. doi: 10.1002/14651858.CD014592.pub2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
475.622
Identifier Type: REGISTRY
Identifier Source: secondary_id
23286013.7.0000.0096
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.